A Phase 1, Open-labeled, Single-dose, One-sequence, One-period, 3-part Study to Investigate the Absorption, Metabolism, Excretion, Absolute Bioavailability, and Immunogenicity of GX-I7 in Healthy Volunteers
Latest Information Update: 03 Feb 2022
At a glance
- Drugs Efineptakin alfa (Primary) ; Efineptakin alfa (Primary)
- Indications Leucopenia
- Focus Pharmacokinetics
Most Recent Events
- 28 Feb 2020 New trial record